Key clinical point: IL-23 targeting antibody shows greater efficacy than TNF-alpha inhibiting antibody.
Major finding: Risankizumab more often led to 90% improvement in PASI (72% versus 47%).
Study details: Randomized, phase 3 trial involving 605 patients with psoriasis.
Disclosures: The study received funding and support from Boehringer Ingelheim and AbbVie. Dr. Lebwohl has consulted for consultant for Allergan, Almirall, Arcutis, Avotres, Birch Biomed, Boehringer Ingelheim, Bristol-Myers Squibb, Cara, Castle Biosciences, Dermavant, Encore, Inozyme, LEO Pharma, Meiji, Menlo, Mitsubishi Pharma, Neuroderm Ltd, Pfizer, Promius, Dr Reddy, Theravance Biopharma, and Verrica.
Reich K, et al. Lancet 2019, July 4.